« Return to News | CROs/Service Providers

WuXi AppTec Partners with Qiagen to Develop Biomarkers

Tuesday, January 12, 2010 06:11 AM

Chinese contract research organization (CRO) WuXi AppTec has entered into a partnership with Netherlands holding company Qiagen to provide biomarker development, validation and personalized healthcare diagnostics. Neither company provided the financial details of the agreement.

Under the terms of the partnership, Qiagen will provide instrumentation, training and consumables at WuXi’s Shanghai campus, and Wuxi will provide the laboratory facilities and the staff. The two companies will promote each other’s services to their respective clients.

According to Qiagen, the partnership creates “the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas.”

"WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said WuXi chairman and CEO Dr. Ge Li in a statement. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.